"10.1371_journal.pone.0144917","plos one","2016-01-05T00:00:00Z","David A Cooper; Damien V Cordery; Roberto Zajdenverg; Kiat Ruxrungtham; Keikawus Arastéh; Frank Bergmann; José L de Andrade Neto; Joseph Scherer; Ricardo L Chaves; Patrick Robinson; study team","The Kirby Institute, University of New South Wales, Sydney, Australia; Head of Medical Affairs, HIV, Infectious Diseases and Immuneinflammatory Diseases, GlaxoSmithKline, Rio de Janeiro, Brazil; HIV-NAT, Thai Red Cross AIDS Research Centre; and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Epimed GmbH, Vivantes Auguste-Viktoria Hospital, Berlin, Germany; Department of Internal Medicine, Infectiology and Pulmonology, Humboldt University, Berlin, Germany; Instituto A Z de Pesquisa E Ensino, Pesquisa E Ensino, Brazil; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States of America; Boehringer Ingelheim GmbH, Ingelheim, Germany","Conceived and designed the experiments: DAC KA JS RLC PR. Performed the experiments: DAC DVC RZ KR KA FB JLAN RLC. Analyzed the data: DAC JS RLC PR. Contributed reagents/materials/analysis tools: JS RLC PR. Wrote the paper: DAC DVC RZ KR KA FB JLAN JS RLC PR.","This study was funded by Boehringer-Ingelheim. Joseph Scherer is currently an employee of Boehringer-Ingelheim Pharmaceuticals, Inc. Patrick Robinson was an employee of Boehringer-Ingelheim during the conduct of the study and the preparation of the manuscript. Ricardo Chaves was formerly employed with Boehringer-Ingelheim Pharmaceuticals, Inc. Roberto Zajdenverg is employed at GlaxoSmithKline, Brazil. Kiat Ruxrungtham has served as a consultant for Merck, Tibotec, and Mylan. He has been paid for speaking engagements with Bristol-Myers Squibb, Merck, Roche, Jensen-Cilag, GlaxoSmithKline, Thai GPO, and Mylan Lab limited. Keikawus Arastéh was speaker, investigator, and advisor as well as country-coordinating investigator (Tranxition study) for Boehringer-Ingelheim Pharmaceuticals, Inc. Frank Bergmann has received support for travel to meetings for the study by Boehringer-Ingelheim Pharmaceuticals, Inc. There are no patents, products in development, or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2016","01","David A Cooper","DAC",11,TRUE,5,8,4,10,TRUE,TRUE,TRUE,1,"11",TRUE
